Phillips Capital has initiated accumulate on Hyphens Pharma with a target price of $0.435. There are several investment merits into this company. Firstly it has “exclusivity as regional product owner for proprietary brands and renowned brand principals from Europe and the United States.” Secondly, the “expansion of sales into B2C channel in Singapore will increase retail presence of Hyphens Pharma’s product portfolio.” Last but not the least, it has a “‘Asset-light’ business model that presents strong value creation.” DBS Equity Research has maintained buy on Riverstone holdings with an increase in target price of $3.90. One of the main reason is because of the huge demand and tight supply of gloves in the world. This will result in higher average selling price, thus margin for Riverstone. “Riverstone’s orderbook is fully locked in till June 2021. Average selling price (ASP) and margins sky-rocketed to new territory amidst this pandemic outbreak. ASP...